Insulin Delivery Devices Market Scope And Analysis

  • Report Code : TIPHE100000819
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

Insulin Delivery Devices Market Scope, Growth, Size and Share by 2025

Buy Now


Insulin Delivery Devices Market Report Scope

Report Attribute Details
Market size in 2023 US$ 21068.90 Million
Market Size by 2031 US$ 41126.08 Million
Global CAGR (2023 - 2031) 8.7%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By Product
  • Insulin Pens
  • Insulin Pumps
  • Insulin Syringes
  • Pen Needles
By End User
  • Patients/Homecare
  • Hospitals & Clinics
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • BD
  • Novo Nordisk A S
  • B Braun Melsungen AG
  • Insulet Corporation
  • Medtronic
  • Tandem Diabetes Care Inc
  • Eli Lilly and Company
  • Biocon
  • Owen Mumford Ltd
  • Sanofi
  • Insulin Delivery Devices Market News and Recent Developments

    The insulin delivery devices market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the insulin delivery devices market are listed below:

    • Novo Nordisk introduced two smart connected insulin pens, NovoPen 6 and NovoPen Echo Plus, which are available on prescription for people living with diabetes treated with Novo Nordisk insulin in the UK. NovoPen 6 and NovoPen Echo Plus are insulin injection pens that record dosing information, including when and how much insulin was administered. (Source: Novo Nordisk, Press Release, March 2022)
    • Eli Lilly and Company launched its insulin glargine biosimilar, Rezvoglar (insulin glargine-agar), on the US market, making it the second interchangeable insulin biosimilar to become commercially available to American patients with diabetes. (Source: Eli Lilly and Company, Press Release, April 2023)

    Insulin Delivery Devices Market Report Coverage and Deliverables

    The “Insulin Delivery Devices Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

    • Insulin delivery devices market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
    • Insulin delivery devices market trends as well as market dynamics such as drivers, restraints, and key opportunities
    • Detailed PEST and SWOT analysis
    • Insulin delivery devices market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
    • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the insulin delivery devices market
    • Detailed company profiles